scholarly journals Current Treatment Options for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

2012 ◽  
Vol 26 (6) ◽  
pp. 353-357 ◽  
Author(s):  
Melanie D Beaton
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lifestyle Modification ◽  
Treatment Options ◽  
Western Society ◽  
Current Status ◽  
Treatment Modalities ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease is the leading cause of liver disease in western society. It is a cause of end-stage liver disease, with increased mortality secondary to cirrhosis and its complications. It is also recognized that cardiovascular disease is a significant cause of death in these patients. Significant work evaluating various treatments has been performed in recent years; however, to date, no ideal therapy exists. Lifestyle modification remains the cornerstone of management. The present article reviews the current status of various treatment modalities evaluated in nonalcoholic fatty liver disease.

scholarly journals Recent Progress in the Molecular Imaging of Nonalcoholic Fatty Liver Disease

2021 ◽  
Vol 22 (14) ◽  
pp. 7348
Author(s):  
Olivia Wegrzyniak ◽  
Maria Rosestedt ◽  
Olof Eriksson
Keyword(s):  
Liver Disease ◽  
Molecular Imaging ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Imaging Techniques ◽  
Current Status ◽  
Nonalcoholic Fatty Liver ◽  
Positron Emission ◽  
Activated Fibroblasts

Pathological fibrosis of the liver is a landmark feature in chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Diagnosis and assessment of progress or treatment efficacy today requires biopsy of the liver, which is a challenge in, e.g., longitudinal interventional studies. Molecular imaging techniques such as positron emission tomography (PET) have the potential to enable minimally invasive assessment of liver fibrosis. This review will summarize and discuss the current status of the development of innovative imaging markers for processes relevant for fibrogenesis in liver, e.g., certain immune cells, activated fibroblasts, and collagen depositions.

scholarly journals Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis

2019 ◽  
Vol 19 (3) ◽  
pp. 187-198 ◽  
Author(s):  
Jia-Zhen Zhang ◽  
Jing-Jing Cai ◽  
Yao Yu ◽  
Zhi-Gang She ◽  
Hongliang Li
Keyword(s):  
Liver Disease ◽  
Liver Biopsy ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Current Status ◽  
Imaging Biomarkers ◽  
Nonalcoholic Fatty Liver ◽  
Advantages And Disadvantages ◽  
Diagnostic Approaches

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease and a major cause of related complications such as cirrhosis and hepatocellular carcinoma (HCC). NAFLD progresses through the stages of simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and HCC. However, NAFLD usually cannot be diagnosed in a timely manner, which is largely attributed to the asymptomatic features of NAFLD patients and the lack of an effective and accurate noninvasive screening approach. Although liver biopsy has been recognized as a gold standard for diagnosing NAFLD, this approach is not suitable for screening and monitoring NAFLD because of its high cost and invasiveness. Several noninvasive screening and diagnostic systemic assessments have been developed in recent years for NAFLD evaluation. Here we summarize the current status and methods for NAFLD diagnosis, including both noninvasive (imaging, biomarkers) and invasive (liver biopsy) assessments. We further discuss the advantages and disadvantages of these developed diagnostic approaches for NAFLD.

scholarly journals A Review of Western and Traditional Chinese Medical Approaches to Managing Nonalcoholic Fatty Liver Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-12 ◽  
Author(s):  
Wei-Fan Hsu ◽  
Lee-Yan Sheen ◽  
Hung-Jen Lin ◽  
Hen-Hong Chang
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Lifestyle Modification ◽  
The United States ◽  
Herbal Remedies ◽  
Nonalcoholic Fatty Liver ◽  
Chinese Herbal ◽  
Increased Risk

Nonalcoholic fatty liver disease (NAFLD) is a disease of attention because of increase in prevalence from 20% to 41%. The clinical and pathological conditions in patients with NAFLD range from steatosis alone to nonalcoholic steatohepatitis (NASH) with or without fibrosis to hepatic cancer. In the United States, NAFLD was the second-leading indication for liver transplant between 2004 and 2013. Although imaging studies such as magnetic resonance elastography and the use of diagnostic panels and scoring systems can provide a fairly accurate diagnosis of NAFLD, there are few treatment options for patients with mild to moderate disease other than lifestyle modification. Many of the currently used medical treatments have been shown to cause severe side effects and some have been shown to be associated with increased risk for certain types of cancer. In recent years, a number of traditional Chinese herbal treatments have been examined for their potential uses as treatment for NAFLD. In this review, we provide a general overview of NAFLD and a survey of Western pharmacologic drugs currently used to treat the disease as well as the results of recent studies on the effectiveness of traditional Chinese herbal remedies for managing nonalcoholic fatty liver disease.

Treatment Options for Nonalcoholic Fatty Liver Disease in Children: A Systematic Review

2014 ◽  
Vol 109 ◽  
pp. S595
Author(s):  
Nidhi Rawal ◽  
Anca Safta ◽  
Anjali Malkani ◽  
Shamila Zawahir ◽  
Runa Watkins ◽  
...  
Keyword(s):  
Systematic Review ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Treatment Options ◽  
Nonalcoholic Fatty Liver

scholarly journals Efficacy of Weight Reduction on Pediatric Nonalcoholic Fatty Liver Disease: Opportunities to Improve Treatment Outcomes Through Pharmacotherapy

2021 ◽  
Vol 12 ◽  
Author(s):  
Chance S. Friesen ◽  
Chelsea Hosey-Cojocari ◽  
Sherwin S. Chan ◽  
Iván L. Csanaky ◽  
Jonathan B. Wagner ◽  
...  
Keyword(s):  
Weight Loss ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Weight Reduction ◽  
Fatty Liver Disease ◽  
Lifestyle Modification ◽  
Drug Repurposing ◽  
Nonalcoholic Fatty Liver ◽  
Treatment And Prevention

Obesity is the single greatest risk factor for nonalcoholic fatty liver disease (NAFLD). Without intervention, most pediatric patients with NAFLD continue to gain excessive weight, making early, effective weight loss intervention key for disease treatment and prevention of NAFLD progression. Unfortunately, outside of a closely monitored research setting, which is not representative of the real world, lifestyle modification success for weight loss in children is low. Bariatric surgery, though effective, is invasive and can worsen NAFLD postoperatively. Thus, there is an evolving and underutilized role for pharmacotherapy in children, both for weight reduction and NAFLD management. In this perspective article, we provide an overview of the efficacy of weight reduction on pediatric NAFLD treatment, discuss the pros and cons of currently approved pharmacotherapy options, as well as drugs commonly used off-label for weight reduction in children and adolescents. We also highlight gaps in, and opportunities for, streamlining obesity trials to include NAFLD assessment as a valuable, secondary, therapeutic outcome measure, which may aid drug repurposing. Finally, we describe the already available, and emerging, minimally-invasive biomarkers of NAFLD that could offer a safe and convenient alternative to liver biopsy in pediatric obesity and NAFLD trials.

Sign in / Sign up

Export Citation Format

Share Document